长期应用非那雄胺治疗良性前列腺增生临床疗效分析

目的 探讨长期应用非那雄胺治疗良性前列腺增生(BPH)的临床疗效及安全性.方法 观察患有BPH并坚持服用非那雄胺5 mg/d治疗7年以上的患者并分析其临床资料.结果 患者治疗前后前列腺体积分别为(48.0±12.5)ml和(41.0±8.4) ml,治疗后前列腺体积明显缩小(t=2.04,P＜0.05).血清前列腺特异抗原(PSA)治疗前后分别为(3.8±1.5)μg/L和(1.5±1.1)μg/L,差异有统计学意义(t=5.30,P＜0.05),治疗后2倍PSA值为(2.9±2.2)μg/L,较治疗前差异无统计学意义(t=1.38,P＞0.05).国际前列腺症状评分(IPSS)治疗后有显著改善[(21.1±7.0)分与(17.1±4.5)分,t=2.09,P＜0.05].治疗期间1例患者发生急性尿潴留,1例患者出现肉眼血尿,未见其他不良反应.结论 长期应用非那雄胺治疗良性BPH疗效好,不良反应小,值得临床推广.

Clinical effects of long-term use of finasteride in treatment of patients with benign prostatic hyperplasia

Objective To evaluate the clinical efficacy and safety of long-term use of finasteride in the treatment of patients with benign prostatic hyperplasia(BPH).Methods The clinical data of patients with BPH receiving finasteride 5 mg daily for more than 7 years were analyzed.Results The prostate volumes were significantly reduced from (48.0 ± 12.5) ml before treatment to (41.0 ±8.4)ml after treatment (t = 2.04,P＜ 0.05 ).The serum levels of prostatic specific antigen (PSA)were (3.8 ± 1.5) μg/L and ( 1.5 ± 1.1 ) μtg/L before and after treatment,respectively(t = 5.30,P＜0.05),but 2 times in PSA post-treatment were (2.9 ± 2.2) μg/L with no difference versus pretreatment (t= 1.38,P＞ 0.05).International prostate symptome score (IPSS) after treatment (17.1±4.5) was significantly improved as compared with pre-treatment (21.1 ± 7.0) (t = 2.09,P＜0.05).1 case with acute urinary retention and 1 case with hematuria occurred and no other side effects were found during treatment.Conclusions Long-term use of finasteride for the treatment of BPH is effective,safe and worthy of wide use.